ARPI
2 products
3 abstracts
Abstract
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.Org: GenesisCare, Fort Myers, FL, Telix Pharmaceuticals (Innovations),
Abstract
Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.Org: Asclepius Analytics, IQVIA, Inc.,
Abstract
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.Org: Global Drug Development, Novartis Pharmaceuticals AG, Basel, Switzerland,